Toshifumi Hibi∥

42.7k total citations · 3 hit papers
788 papers, 26.6k citations indexed

About

Toshifumi Hibi∥ is a scholar working on Genetics, Epidemiology and Surgery. According to data from OpenAlex, Toshifumi Hibi∥ has authored 788 papers receiving a total of 26.6k indexed citations (citations by other indexed papers that have themselves been cited), including 350 papers in Genetics, 320 papers in Epidemiology and 265 papers in Surgery. Recurrent topics in Toshifumi Hibi∥'s work include Inflammatory Bowel Disease (332 papers), Microscopic Colitis (208 papers) and Helicobacter pylori-related gastroenterology studies (130 papers). Toshifumi Hibi∥ is often cited by papers focused on Inflammatory Bowel Disease (332 papers), Microscopic Colitis (208 papers) and Helicobacter pylori-related gastroenterology studies (130 papers). Toshifumi Hibi∥ collaborates with scholars based in Japan, United States and Canada. Toshifumi Hibi∥'s co-authors include Hidekazu Suzuki, Takanori Kanai∥, Haruhiko Ogata, Tadakazu Hisamatsu, Mamoru Watanabe, Taku Kobayashi, Nobuhiko Kamada, Hiromasa Ishii, Yasushi Iwao and Nagamu Inoue and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Toshifumi Hibi∥

752 papers receiving 26.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Ulcerative colitis

2020 1.1k citations Taku Kobayashi, Silvio Danese et al. profile →
Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis

2013 701 citations Brian G. Feagan, Toshifumi Hibi∥ et al. Gastroenterology profile →
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease☆

2004 507 citations Toshifumi Hibi∥, Akira Andoh et al. Gastroenterology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Toshifumi Hibi∥ Japan	81	9.9k	8.3k	7.6k	7.1k	5.3k	788	26.6k
Gerhard Rogler Switzerland	76	11.0k 1.1×	7.6k 0.9×	6.9k 0.9×	5.6k 0.8×	7.7k 1.5×	645	26.9k
Jürgen Schölmerich Germany	85	7.6k 0.8×	10.4k 1.3×	7.4k 1.0×	5.1k 0.7×	5.5k 1.0×	561	29.1k
Julián Panés Spain	84	14.2k 1.4×	11.2k 1.4×	8.5k 1.1×	4.8k 0.7×	2.8k 0.5×	590	26.0k
Marc Ferrante Belgium	64	12.4k 1.3×	8.9k 1.1×	5.3k 0.7×	4.7k 0.7×	4.6k 0.9×	543	21.4k
Stephan R. Targan United States	90	18.3k 1.8×	12.5k 1.5×	6.0k 0.8×	11.5k 1.6×	4.4k 0.8×	434	31.0k
María T. Abreu United States	76	10.1k 1.0×	7.3k 0.9×	5.0k 0.7×	6.4k 0.9×	4.8k 0.9×	378	21.4k
Eduard F. Stange Germany	64	8.3k 0.8×	6.0k 0.7×	5.4k 0.7×	3.6k 0.5×	5.1k 1.0×	300	18.4k
R. Balfour Sartor United States	87	8.9k 0.9×	5.8k 0.7×	5.0k 0.7×	7.1k 1.0×	16.4k 3.1×	336	32.0k
Gert Van Assche Belgium	92	26.9k 2.7×	20.6k 2.5×	10.7k 1.4×	8.9k 1.2×	3.2k 0.6×	476	36.8k
Siew C. Ng Hong Kong	83	10.1k 1.0×	7.5k 0.9×	8.5k 1.1×	3.1k 0.4×	10.5k 2.0×	412	30.3k

Countries citing papers authored by Toshifumi Hibi∥

Since Specialization

Citations

This map shows the geographic impact of Toshifumi Hibi∥'s research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Toshifumi Hibi∥ with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Toshifumi Hibi∥ more than expected).

Fields of papers citing papers by Toshifumi Hibi∥

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Toshifumi Hibi∥. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Toshifumi Hibi∥. The network helps show where Toshifumi Hibi∥ may publish in the future.

Co-authorship network of co-authors of Toshifumi Hibi∥

This figure shows the co-authorship network connecting the top 25 collaborators of Toshifumi Hibi∥. A scholar is included among the top collaborators of Toshifumi Hibi∥ based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Toshifumi Hibi∥. Toshifumi Hibi∥ is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hibi∥, Toshifumi, Taku Kobayashi, Masaru Tanaka, et al.. (2025). Patient and Health Care Professional Perspectives on the Burden and Daily Life Impact of Ulcerative Colitis and Crohn’s Disease: Results from the Japanese CONFIDE Study. Advances in Therapy. 42(4). 1834–1859. 2 indexed citations

Kobayashi, Taku, Katsuyoshi Matsuoka, Mamoru Watanabe, et al.. (2024). Efficacy and safety of mirikizumab as induction and maintenance therapy for Japanese patients with moderately to severely active ulcerative colitis: a subgroup analysis of the global phase 3 LUCENT-1 and LUCENT-2 studies. Intestinal Research. 22(2). 172–185. 5 indexed citations

Sagami, Shintaro, et al.. (2024). Early change in serum leucine-rich α-2-glycoprotein predicts clinical and endoscopic response in ulcerative colitis. Intestinal Research. 22(4). 473–483. 4 indexed citations

Hibi∥, Toshifumi, Shunsei Hirohata, Tadakazu Hisamatsu, et al.. (2024). Real-World Safety and Effectiveness of Infliximab in 255 Patients with Intestinal, Neurological, and Vascular Behçet’s Disease: A Post-Marketing Surveillance. Advances in Therapy. 41(12). 4476–4497. 4 indexed citations

Regueiro, Miguel, Monika Fischer, Peter Bossuyt, et al.. (2024). Mirikizumab Sustained Impact on Fatigue in Patients with Moderately to Severely Active Crohn’s Disease in the Phase 2 AMAG Study. Inflammatory Bowel Diseases. 31(2). 432–441. 4 indexed citations

Sagami, Shintaro, et al.. (2024). Leucine‐Rich Alpha‐2 Glycoprotein Is Associated With Transmural Inflammation Assessed by Intestinal Ultrasound in Patients With Crohn's Disease. Alimentary Pharmacology & Therapeutics. 61(4). 658–666. 1 indexed citations

Dubinsky, Marla C., Vipul Jairath, Brian G. Feagan, et al.. (2023). Changes in health-related quality of life and associations with improvements in clinical efficacy: a Phase 2 study of mirikizumab in patients with ulcerative colitis. BMJ Open Gastroenterology. 10(1). e001115–e001115. 8 indexed citations

Takeuchi, Tsutomu, Kiyohiro Nishikawa, Akimichi Morita, et al.. (2023). Real-World Safety and Efficacy of Biosimilar CT-P13 in Patients with Immune-Mediated Inflammatory Diseases: Integrated Analysis of Three Japanese Prospective Observational Studies. Drug Safety. 46(10). 991–1005. 3 indexed citations

Rubin, David T., et al.. (2023). 963 BOWEL URGENCY OUTCOMES ARE ASSOCIATED WITH IMPROVEMENT IN FATIGUE IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: A POOLED ANALYSIS OF LUCENT-1 AND LUCENT-2 PHASE 3 TRIALS. Gastroenterology. 164(6). S–213. 2 indexed citations

10.

Matsuoka, Katsuyoshi & Toshifumi Hibi∥. (2023). Author Correction: Etrasimod for ulcerative colitis: evaluating phase III results. Nature Reviews Gastroenterology & Hepatology. 20(12). 829–829. 1 indexed citations

11.

Okabayashi, Shinji, Hajime Yamazaki, Keiichi Tominaga, et al.. (2022). Lower effectiveness of intravenous steroid treatment for moderate‐to‐severe ulcerative colitis in hospitalised patients with older onset: a multicentre cohort study. Alimentary Pharmacology & Therapeutics. 55(12). 1569–1580. 8 indexed citations

12.

Schreiber, Stefan, Shomron Ben‐Horin, Rieke Alten, et al.. (2022). Perspectives on Subcutaneous Infliximab for Rheumatic Diseases and Inflammatory Bowel Disease: Before, During, and After the COVID-19 Era. Advances in Therapy. 39(6). 2342–2364. 22 indexed citations

13.

Sagami, Shintaro, Taku Kobayashi, Shinji Okabayashi, et al.. (2020). Accuracy of Ultrasound for Evaluation of Colorectal Segments in Patients With Inflammatory Bowel Diseases: A Systematic Review and Meta-analysis. Clinical Gastroenterology and Hepatology. 19(5). 908–921.e6. 60 indexed citations

14.

Suzuki, Yasuo, Satoshi Motoya, Hiroyuki Hanai, et al.. (2013). Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis. Journal of Gastroenterology. 49(2). 283–294. 133 indexed citations

15.

Nishizawa, Toshihiro, Hidekazu Suzuki, Masayuki Suzuki, Masahiko Takahashi, & Toshifumi Hibi∥. (2012). Proton pump inhibitor-amoxicillin-clarithromycin versus proton pump inhibitor-amoxicillin-metronidazole as first-line Helicobacter pylori eradication therapy. Journal of Clinical Biochemistry and Nutrition. 51(2). 114–116. 29 indexed citations

16.

Kishikawa, Hiroshi, Jiro Nishida, Hitoshi Ichikawa, et al.. (2011). Serum Nitrate/Nitrite Concentration Correlates with Gastric Juice Nitrate/Nitrite: A Possible Marker for Mutagenesis of the Proximal Stomach. Digestion. 84(1). 62–69. 7 indexed citations

17.

Tsugawa, Hitoshi, Hidekazu Suzuki, Kazue Satoh, et al.. (2010). Two Amino Acids Mutation of Ferric Uptake Regulator Determines Helicobacter pylori Resistance to Metronidazole. Antioxidants and Redox Signaling. 14(1). 15–23. 52 indexed citations

18.

Suzuki, Hidekazu, Juntaro Matsuzaki, & Toshifumi Hibi∥. (2010). Ghrelin and oxidative stress in gastrointestinal tract. Journal of Clinical Biochemistry and Nutrition. 48(2). 122–125. 67 indexed citations

19.

Fukushima, Kouhei, Hisao Fujii, Takehira Yamamura, et al.. (2007). Pouchitis atlas for objective endoscopic diagnosis. Journal of Gastroenterology. 42(10). 799–806. 14 indexed citations

20.

Arai, Jun, Nagamu Inoue, Haruhiko Ogata, et al.. (2002). Combination therapy of continuous arterial infusion of nafamostat mesilate and arterial injection of human urinary trypsin inhibitor (ulinastatin) for severe acute pancreatitis. 23(6). 1265–1275. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact